YEZTUGO (lenacapavir) – a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor drug therapy in India.
YEZTUGO, a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating YEZTUGO
| Brand Name: | YEZTUGO |
| Generic Name: | lenacapavir Injection |
| Strength: | • Tablets: 300 mg of lenacapavir • Injection: 463.5 mg/1.5 mL (309 mg/mL) of lenacapavir in single-dose vials |
| Manufacturer: | Gilead Sciences, Inc. |
| Approved By: | EMA, USFDA |
Source Details: Patient Information.
YEZTUGO must always be used under the supervision of a Registered Medical Practitioner (RMP).
Access YEZTUGO for for pre-exposure prophylaxis (PrEP) on a Named Patient Import Basis
IPN, New Delhi serves as a facilitator for the procurement of specialized drugs on behalf of patients or treating doctors, enabling access to YEZTUGO (lenacapavir) for personal use. To proceed, the applicant must submit an application in Form 12A along with a valid prescription issued by a Registered Medical Practitioner (RMP).
For any queries, including information regarding the cost of the pharmaceutical product in India, please contact the IPN Healthcare Support Team via email or at the following numbers: Mobile/WhatsApp: Mr. Tarun: +91 9891 296 838 | Mr. Neeraj: +91 9811 747 774.
Note: All access is provided strictly on a Named Patient Import Basis and for personal use only, in accordance with Indian regulatory guidelines.